What do 10,000 studies in your therapeutic area say that no one has read?
Neoastis maps cross-study relationships across 39M+ PubMed citations, congress data, and your internal assets — with 100% source-verified outputs. Then our strategists turn the map into decisions.
30+ years of pharma leadership behind every recommendation
Ingest. Map. Strategize.
1 · Ingest
39M+ PubMed records, global congress data, and your internal assets — cleaned, classified, and indexed in minutes, not months.
2 · Map
Proprietary NLP surfaces hidden cross-study relationships. Every link traceable to its source. No hallucinated connections.
3 · Strategize
Senior pharma strategists validate the patterns and convert them into patient profiles, positioning, and access strategy.
Use Cases
Patient profiling & therapy positioning
Pharma AI strategy & governance
RWD & patient flow modeling
We map unmet needs across 10,000+ therapeutic studies to surface „delighter“ insights, sharpen brand positioning, and generate publication-ready medical evidence.
We bridge the gap between IT-built AI pilots and compliant, evidence-based Medical Affairs and Commercial practice — with governance that stands up to scrutiny.
Real-life clinical data fused with literature to forecast line-of-therapy transitions, dropout risk, and market share — before your competitors see the curve.
Medical affairsBrand teamsLeadershipComplianceForecastingMarket access
Bridging advanced AI architecture with 30+ years of pharma leadership
„Neoastis exists because the bottleneck in pharma strategy was never data. It was the distance between the data and the decision.“
Science & craft
PhD in Technical Physics · INSEAD MBA · Six Sigma Greenbelt · founder of Neoastis AI and digital-health platform Netwelly.
Pharma executive
AbbVie · Novartis · Janssen · Sandoz — business unit, brand, decision support, and commercial leadership across neuroscience and hematology.
Top-tier consulting
The Boston Consulting Group · BearingPoint (Apple Retail setup) · applied industrial informatics.